Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Baxter
Johnson and Johnson
McKesson
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

VELETRI Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Veletri patents expire, and when can generic versions of Veletri launch?

Veletri is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighteen patent family members in fourteen countries.

The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.

Drug patent expirations by year for VELETRI
Drug Prices for VELETRI

See drug prices for VELETRI

Recent Clinical Trials for VELETRI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 4

See all VELETRI clinical trials

Recent Litigation for VELETRI

Identify potential future generic entrants

District Court Litigation
Case NameDate
ACTELION PHARMACEUTICALS LTD. v. SUN PHARMACEUTICAL INDUSTRIES, INC.2017-07-07

See all VELETRI litigation

Pharmacology for VELETRI
Drug ClassProstacycline Vasodilator
Physiological EffectVasodilation
Synonyms for VELETRI
(5Z,13E,8R,9S,11R,12R,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid sodium salt
(5Z,9|A,11|A,13E,15S)-6,9-epoxy-11,15-Dihydroxy-prosta-5,13-dien-1-oic Acid Sodium Salt
4K04IQ1OF4
4UA76
61849-14-7
91284-07-0
AC1O4BXH
ACT-385781A
AKOS024457370
BML1-F10
C20H31NaO5
C20H31O5.Na
CAS-61849-14-7
CHEMBL962
Cyclo-Prostin
DSSTox_CID_26617
DSSTox_GSID_46617
DSSTox_RID_81769
DTXSID3046617
EINECS 263-273-7
Epoprostenol sodium
Epoprostenol sodium [USAN:BAN]
Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
Epoprostenolsodium
Flolan
Floran
HMS1361K18
HMS3648L14
LMHIPJMTZHDKEW-XQYLJSSYSA-M
LS-176206
MolPort-006-132-470
NCGC00167427-01
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, sodium salt, (5Z,9alpha,11alpha,13E,15S)-
prostacyclin
Prostacyclin sodium
Prostacyclin sodium salt
PROSTAGLANDIN I2 Na
Prostaglandin I2 sodium
Prostaglandin X sodium
SCHEMBL41344
Sodium (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dien-1-oate
sodium (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate
Sodium (Z)-(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valerate
sodium (Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoate
Sodium prostacyclin
Tox21_112431
U 53,217A
U-53,217A
U-53217A
UNII-4K04IQ1OF4
V0155
Paragraph IV (Patent) Challenges for VELETRI
Tradename Dosage Ingredient NDA Submissiondate
VELETRI INJECTABLE;INJECTION epoprostenol sodium 022260 2017-03-31

US Patents and Regulatory Information for VELETRI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-001 Jun 27, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-001 Jun 27, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
AstraZeneca
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.